312 related articles for article (PubMed ID: 29222310)
1. Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):605-609. PubMed ID: 29222310
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
Meeks SL; Batsuli G
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
[TBL] [Abstract][Full Text] [Related]
3. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
4. Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.
Ebert M; Raquet E; Schweisgut S; Schmidt PM; Weimer T
Blood Cells Mol Dis; 2021 Jul; 89():102570. PubMed ID: 33962291
[TBL] [Abstract][Full Text] [Related]
5. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutics for hemophilia and other bleeding disorders.
Callaghan MU; Sidonio R; Pipe SW
Blood; 2018 Jul; 132(1):23-30. PubMed ID: 29769259
[TBL] [Abstract][Full Text] [Related]
7. [Hemostatic management of hemophilia].
Tokugawa T
Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.
Young G; Escobar MA; Pipe SW; Cooper DL
Am J Hematol; 2017 Sep; 92(9):940-945. PubMed ID: 28589615
[TBL] [Abstract][Full Text] [Related]
10. Longer-acting clotting factor concentrates for hemophilia.
Powell JS
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S167-75. PubMed ID: 26149018
[TBL] [Abstract][Full Text] [Related]
11. Non-factor replacement therapy for haemophilia: a current update.
Franchini M; Mannucci PM
Blood Transfus; 2018 Sep; 16(5):457-461. PubMed ID: 29517971
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy.
Shibata M; Nakagawa T; Akioka S; Giddings JC; Kanehiro H; Matsumoto T; Ogiwara K; Yada K; Shima M
Clin Appl Thromb Hemost; 2012; 18(1):66-71. PubMed ID: 21733937
[TBL] [Abstract][Full Text] [Related]
13. A case report of a premature infant with haemophilia A and factor VIII inhibitor.
Cartledge P; Deakin K; McKecknie L; Richards M
Haemophilia; 2011 Jul; 17(4):711-2. PubMed ID: 21371187
[No Abstract] [Full Text] [Related]
14. Milestones in hemophilia and concepts in future clinical trial design.
Lusher JM
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S84-7. PubMed ID: 16427391
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab for hemophilia A with factor VIII inhibitors.
Young G; Callaghan M; Dunn A; Kruse-Jarres R; Pipe S
Expert Rev Hematol; 2018 Nov; 11(11):835-846. PubMed ID: 30278802
[TBL] [Abstract][Full Text] [Related]
16. [Current developments in hemostatic treatment for patients with hemophilia].
Nogami K
Rinsho Ketsueki; 2021; 62(8):1213-1221. PubMed ID: 34497209
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor development, safety and efficacy of Advate
Fukutake K; Taki M; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
Int J Hematol; 2019 Mar; 109(3):336-345. PubMed ID: 30604312
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia patients: are they naturally anticoagulated?
Tripodi A; Mannucci PM; Peyvandi F
Intern Emerg Med; 2023 Aug; 18(5):1251-1254. PubMed ID: 37515677
[TBL] [Abstract][Full Text] [Related]
19. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors.
Hedner U
J Thromb Haemost; 2006 Nov; 4(11):2498-500. PubMed ID: 16907841
[No Abstract] [Full Text] [Related]
20. [Perioperative use of recombinant activated factor VII (rF VIIa) in a patient with hemophilia A having inhibitors].
Kawasaki Y; Saeki N; Kawamoto M; Yuge O; Fujii T
Masui; 2005 Aug; 54(8):926-8. PubMed ID: 16104555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
